Orphan Training & Education Facilities

Orphanage Update news:

• NeoPharm Announces Orphan Drug Application Filing For IL13-PE38QQR For The Treatment Of Idiopathic Pulmonary Fibrosis (Medical News Today)
  NeoPharm, Inc. (Other OTC: NEOL.PK), announced that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) to have Orphan Drug Designation granted to IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The US Orphan Drug Act is intended to assist and encourage companies to develop ...
  


• Bayer HealthCare Pharmaceuticals' ciprofloxacin DPI granted FDA orphan drug designation for CF treatment (News-Medical-Net)
  Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration for ciprofloxacin dry powder inhaler for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients. A similar designation has already been granted by the European Medicines Agency.